Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BDC 4182

Next Previous
Drug Profile

BDC 4182

Alternative Names: BD-4182; BDC4182

Latest Information Update: 20 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bolt Biotherapeutics
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoprotein stimulants; Apoptosis inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Gastric cancer; Oesophageal cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 08 May 2025 Bolt Biotherapeutics plans a phase I/II trial for Gastric cancer (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) and Oesophageal cancer (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in Australia in the second quarter of 2025 (NCT06921837)
  • 04 May 2025 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in Australia (Parenteral) (NCT06921837)
  • 04 May 2025 Phase-I/II clinical trials in Oesophageal cancer (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in Australia (Parenteral) (NCT06921837)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top